Companies / Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc.
Nasdaq: ZVRACIK 1434647BOSTON, MA
Financials · FY2015
Ownership
59.4M shares outstanding · as of Jul 31, 2026
Ownership
| Insiders | 1.11% | 662,135 |
| Institutions | 65.62% | 38,967,838 |
| Public float | 33.26% | 19,753,808 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 9
View all →| Insider | % of shares | Shares |
|---|---|---|
McFarlane Neil F.CEOPresident and CEO · Director | 0.65% | 387,225 |
| 0.24% | 143,515 | |
Bode John BDirector | 0.21% | 123,400 |
| 0.10% | 62,278 | |
Thompson RahsaanChief Legal & Compliance | 0.08% | 49,919 |
Sangiovanni Timothy J.SVP, Finance & Corp Controller | 0.05% | 29,590 |
Quartel Adrian WChief Medical Officer | 0.02% | 9,723 |
Favorito Tamara aDirector | — | — |
| — | — |
Institutional holders 164
View all →| Holder | Value | % of shares |
|---|---|---|
| $73.26M | 8.60% | |
| $30.92M | 5.81% | |
| $29.61M | 5.57% | |
| $24.12M | 2.83% | |
| $21.45M | 4.03% | |
| $15.88M | 2.98% | |
| $12.79M | 2.31% | |
| $10.37M | 1.95% | |
| $9.84M | 1.85% | |
| $8.11M | 1.52% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common stock | $8.63M | +602K +13.35% | 5,108,871 8.60% of shares | medium |
| Q1 2026 as of | Millennium Management LLC 13F manager | Trim | Common stock | $-5.07M | -544K -47.96% | 590,269 0.99% of shares | medium |
| Q1 2026 as of | Flputnam Investment Management Co 13F manager | New | Common stock | $3.27M | +351K | 350,501 0.59% of shares | low |
| Q2 2025 as of | Barclays PLC 13F manager | Trim | Common stock | $-2.91M | -330K -75.99% | 104,351 0.18% of shares | low |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common stock | $2.85M | +199K +13.42% | 1,681,999 2.83% of shares | low |
| Q3 2025 as of | Barclays PLC 13F manager | Add | Common stock | $2.17M | +228K +218.58% | 332,443 0.56% of shares | low |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | Trim | Common stock | $-2.14M | -230K -34.31% | 439,952 0.74% of shares | low |
| Q4 2025 as of | Barclays PLC 13F manager | Trim | Common stock | $-2.08M | -232K -69.88% | 100,135 0.17% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Vanguard Group Inc | Passive13G/A | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| ZVRA | — | 488445206 |